KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $14.2 million.

  • Travere Therapeutics' Free Cash Flow rose 13335.22% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.8 million, marking a year-over-year increase of 7793.15%. This contributed to the annual value of -$237.5 million for FY2024, which is 2716.05% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Free Cash Flow is $14.2 million, which was up 13335.22% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Free Cash Flow registered a high of $31.7 million during Q3 2021, and its lowest value of -$119.0 million during Q1 2024.
  • In the last 5 years, Travere Therapeutics' Free Cash Flow had a median value of -$42.5 million in 2024 and averaged -$48.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 63293.27% in 2021, then tumbled by 67598.94% in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' Free Cash Flow stood at -$88.5 million in 2021, then rose by 13.27% to -$76.7 million in 2022, then grew by 16.08% to -$64.4 million in 2023, then soared by 44.53% to -$35.7 million in 2024, then skyrocketed by 139.69% to $14.2 million in 2025.
  • Its Free Cash Flow was $14.2 million in Q3 2025, compared to $5.0 million in Q2 2025 and -$42.2 million in Q1 2025.